Thomas Graham, Alan, Irving Kahns
Kahn Brothers Group
Kahn Brothers Group Novartis AG ADR stake
total: 111
Kahn Brothers Group NVS trades
- Total transactions:
- 36
- New positions:
- 1
- Added:
- 13
- Reduced:
- 22
- Held since:
- 2013 Q2 or earlier
- Held for:
- 53+ quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Kahn Brothers Group holds 13,186 Novartis AG ADR (NVS) shares with a market value of roughly $2.07M accounting for 0.33% of the overall portfolio. Kahn Brothers Group has held NVS since at least 2013 Q2 with 30,368 shares in our earliest available record. Since at least 2013 Q2, Kahn Brothers Group has made 35 more transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $79.54
- Weighted AVG sell price:
- $97.45
Kahn Brothers Group's historical trades in Novartis AG ADR
36 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.33%
|
13,186
|
$156.72
|
$2,066,509
|
-1.49% (-200)
|
-0.01%
|
|
2026 Q1
|
0.36%
|
13,386
|
$152.75
|
$2,044,711
|
-2.13% (-292)
|
-0.01%
|
|
2025 Q4
|
0.33%
|
13,678
|
$137.87
|
$1,885,785
|
-4.52% (-648)
|
-0.02%
|
|
2025 Q3
|
0.35%
|
14,326
|
$128.24
|
$1,837,166
|
-22.44% (-4,145)
|
-0.11%
|
|
2025 Q2
|
0.45%
|
18,471
|
$121.01
|
$2,235,175
|
-15.69% (-3,438)
|
-0.08%
|
|
2025 Q1
|
0.49%
|
21,909
|
$111.50
|
$2,442,776
|
+3.44% (+728)
|
+0.02%
|
|
2024 Q4
|
0.45%
|
21,181
|
$97.29
|
$2,060,772
|
+20.48% (+3,600)
|
+0.08%
|
|
2024 Q2
|
0.31%
|
17,581
|
$106.46
|
$1,871,752
|
+14.07% (+2,168)
|
+0.04%
|
|
2024 Q1
|
0.22%
|
15,413
|
$96.74
|
$1,491,076
|
-14.67% (-2,650)
|
-0.04%
|
|
2023 Q4
|
0.29%
|
18,063
|
$100.99
|
$1,824,164
|
-16.29% (-3,515)
|
-0.06%
|
|
2022 Q4
|
0.26%
|
$90.73
|
-6.50% (-1,500)
|
|||
|
2022 Q2
|
0.26%
|
$84.51
|
+3.13% (+700)
|
|||
|
2021 Q4
|
0.27%
|
$87.47
|
+9.71% (+1,980)
|
|||
|
2021 Q1
|
0.27%
|
$85.48
|
-8.93% (-2,000)
|
|||
|
2020 Q4
|
0.37%
|
$94.43
|
-1.32% (-300)
|
|||
|
2020 Q2
|
0.33%
|
$87.34
|
-2.16% (-500)
|
|||
|
2020 Q1
|
0.35%
|
$82.45
|
-9.99% (-2,575)
|
|||
|
2019 Q2
|
0.29%
|
$91.31
|
+13.32% (+3,029)
|
|||
|
2018 Q4
|
0.35%
|
$85.81
|
-2.01% (-466)
|
|||
|
2018 Q2
|
0.28%
|
$75.54
|
+5.45% (+1,200)
|
|||
|
2018 Q1
|
0.28%
|
$80.85
|
-17.29% (-4,600)
|
|||
|
2017 Q4
|
0.35%
|
$83.96
|
+1.78% (+466)
|
|||
|
2017 Q3
|
0.34%
|
$85.85
|
-0.26% (-67)
|
|||
|
2017 Q2
|
0.33%
|
$83.47
|
-6.09% (-1,700)
|
|||
|
2017 Q1
|
0.36%
|
$74.27
|
+3.10% (+840)
|
|||
|
2016 Q4
|
0.33%
|
$72.84
|
-2.07% (-572)
|
|||
|
2015 Q4
|
0.42%
|
$86.04
|
-3.15% (-900)
|
|||
|
2015 Q3
|
0.49%
|
$91.92
|
+1.42% (+400)
|
|||
|
2015 Q2
|
0.47%
|
$98.34
|
-9.12% (-2,825)
|
|||
|
2014 Q4
|
0.49%
|
$92.66
|
+1.98% (+600)
|
|||
|
2014 Q3
|
0.46%
|
$94.13
|
+15.17% (+4,000)
|
|||
|
2014 Q2
|
0.35%
|
$90.53
|
-6.06% (-1,700)
|
|||
|
2014 Q1
|
0.34%
|
$85.02
|
+2.56% (+700)
|
|||
|
2013 Q4
|
0.38%
|
$80.38
|
-6.81% (-2,000)
|
|||
|
2013 Q3
|
0.33%
|
$76.71
|
-3.29% (-1,000)
|
|||
|
2013 Q2
|
0.33%
|
$70.71
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.